Filing Flows › Collegium Pharmaceutical (COLL) › Jornay PM revenue
Collegium Pharmaceutical (COLL) Jornay PM revenue by quarter
Collegium Pharmaceutical's Jornay PM revenue was $51.9M in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 6 quarters it ranged from $28.5M (Q1 2025) to $51.9M (Q3 2026).
| Quarter | Jornay PM revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $51.9M | +13% | +24% |
| Q2 2026 | $46.1M | +18% | +41% |
| Q1 2026 | $38.9M | -7% | +36% |
| Q3 2025 | $41.8M | +28% | — |
| Q2 2025 | $32.6M | +14% | — |
| Q1 2025 | $28.5M | — | — |
Q3 2026 at a glance
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Collegium Pharmaceutical's Jornay PM revenue?
Collegium Pharmaceutical's Jornay PM revenue was $51.9M in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has Collegium Pharmaceutical's Jornay PM revenue changed?
Over the last 6 quarters it ranged from $28.5M (Q1 2025) to $51.9M (Q3 2026).
Q3 2026 results → · How Collegium Pharmaceutical makes money →